From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history [0.03%]
从模型精神病到快速抗抑郁剂：氯胺酮的精神病学历史的历史和概念回顾
Casimiro Cabrera Abreu,Aleksandar Biorac,Ross J Baldessarini et al.
Casimiro Cabrera Abreu et al.
Ketamine's development in psychiatry exemplifies the evolution of psychopharmacology over six decades. Originally introduced as a dissociative anesthetic and psychotomimetic probe, ketamine has been repositioned as a rapidly acting antidepr...
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial [0.03%]
持续性抑郁患者微量服用LSD体验的质性研究
Carina Joy Donegan,Dimitri Daldegan-Bueno,Rachael L Sumner et al.
Carina Joy Donegan et al.
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depr...
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine [0.03%]
新型迷幻疗法在创伤后应激障碍治疗中的应用及其精准医疗前景
Charles Dodds,Rachelle Dawson,Alexander Lim et al.
Charles Dodds et al.
Novel interventions for post-traumatic stress disorder (PTSD) leverage the psychoactive properties of psychedelic compounds, such as ketamine, 3,4-methylenedioxymethamphetamine and psilocybin, which may overcome limitations of conventional ...
Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis [0.03%]
评论：致幻剂治疗对精神疾病诊断患者的自杀意念、企图和死亡的影响：系统评价和meta分析
Tiago Machado,Alexandra S L Rodrigues,João Costa
Tiago Machado
Jim van Schie,Peter Lucassen,Tom Birkenhäger et al.
Jim van Schie et al.
Background: Many antidepressant users experience the process of stopping as challenging because of withdrawal symptoms. Support factors, such as patients experiencing empathy from their healthcare providers, potentially c...
Aleksander Kwaśny,Wiesław Jerzy Cubała,Alina Wilkowska
Aleksander Kwaśny
Background: Intravenous ketamine is effective in treatment-resistant bipolar depression (TRBD) with dosing typically based on actual body weight (ABW). Ob...
The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences [0.03%]
受控辅助治疗中疗愈性触摸的伦理使用：研究人员视角与体验的质性研究
Diana McHerron,Michaela Barber,Rachel Ham et al.
Diana McHerron et al.
Background: Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physical contact, supportive touch and somatic techniques. However, p...
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis [0.03%]
氯胺酮与艾司氯胺酮治疗抑郁的系统评价和meta分析
Ahmed Elmosalamy,Idil Tarikogullari,Liliana Patarroyo-Rodriguez et al.
Ahmed Elmosalamy et al.
Background: Depression affects approximately 5.7% of adults worldwide, and around one-third of these individuals develop treatment-resistant depression (TRD). Intravenous (IV) ketamine and esketamine (administered IV or i...
Corrigendum to "Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design" [0.03%]
对“迷幻辅助疗法作为复杂干预措施：临床试验设计的影响”的勘误通知
[This corrects the article DOI: 10.1177/20451253251381074.]. © The Author(s), 2025.
Psychotropic medications adherence status and its determinants among older adults with severe affective and psychotic disorders: a multicenter cross-sectional study [0.03%]
老年严重心境障碍和精神病患者精神药物依从性及其影响因素的多中心横断面研究
Woretaw Sisay Zewdu,Tigabu Eskeziya Zerihun,Desalegn Addis Mussie et al.
Woretaw Sisay Zewdu et al.
Background: Nonadherence jeopardizes treatment outcomes in the psychiatric care continuum. However, there was a paucity of data in the resource-limited life trajectories. ...